from Wiktionary, Creative Commons Attribution/Share-Alike License
- n. An experimental drug, so far shown to reduce tumour growth, metastasis, and angiogenesis.
Sorry, no etymologies found.
Bloomberg reports that the company anticipates takeover offers following positive results in a study of its experimental prostate cancer treatment, cabozantinib, and that some large pharmaceutical companies have shown interest, citing an unnamed person with knowledge of the matter.
The company plans to launch a late-stage study of cabozantinib in prostate cancer in the second half of this year.
And on Monday, Exelixis Inc. reported promising results from a midstage, or Phase II, study of its drug cabozantinib, in advanced prostate cancer.
Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound.
During each presentation, Dr. Morrissey will provide a general business update, review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer, and discuss the pivotal trial plans and regulatory strategy for the compound.
Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients.
During the presentation, Dr. Schwab will review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer CRPC and discuss the pivotal trial plans and regulatory strategy for the compound in CRPC.